title: MicroRNAs in Neurocognitive Dysfunctions: New Molecular Targets for Pharmacological Treatments?
abstract: BACKGROUND
  Neurodegenerative and cognitive disorders are multifactorial diseases (i.e., involving neurodevelopmental, genetic, age or environmental factors) characterized by an abnormal development that affects neuronal function and integrity. Recently, an increasing number of studies revealed that the dysregulation of microRNAs (miRNAs) may be involved in the etiology of cognitive disorders as Alzheimer, Parkinson, and Huntington's diseases, Schizophrenia and Autism spectrum disorders.
  
  
  METHODS
  From an extensive search in bibliographic databases of peer-reviewed research literature, we identified relevant published studies related to specific key words such as memory, cognition, neurodegenerative disorders, neurogenesis and miRNA. We then analysed, evaluated and summerized scientific evidences derived from these studies.
  
  
  RESULTS
  We first briefly summarize the basic molecular events involved in memory, a process inherent to cognitive disease, and then describe the role of miRNAs in neurodevelopment, synaptic plasticity and memory. Secondly, we provide an overview of the impact of miRNA dysregulation in the pathogenesis of different neurocognitive disorders, and lastly discuss the feasibility of miRNA-based therapeutics in the treatment of these disorders.
  
  
  CONCLUSIONS
  This review highlights the molecular basis of neurodegenerative and cognitive disorders by focusing on the impact of miRNAs dysregulation in these pathological phenotypes. Altogether, the published reports suggest that miRNAs-based therapy could be a viable therapeutic alternative to current treatment options in the future.
authors.forename: Wissem Deraredj
authors.initials: WD
authors.lastname: Nadim
authors.forename: Viorel
authors.initials: V
authors.lastname: Simion
authors.forename: Helene
authors.initials: H
authors.lastname: Benedetti
authors.forename: Chantal
authors.initials: C
authors.lastname: Pichon
authors.forename: Patrick
authors.initials: P
authors.lastname: Baril
authors.affiliation: Centre de Biophysique Moleculaire, CNRS UPR4301, Universite d&#39;Orleans France, 45071 Orleans Cedex, France.
authors.forename: Severine
authors.initials: S
authors.lastname: Morisset-Lopez
mesh_terms: D000818:Animals; D000070416:Antagomirs / Q000494:pharmacology / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000235:genetics; D016206:Databases, Bibliographic / Q000706:statistics & numerical data; D005786:Gene Expression Regulation / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D035683:MicroRNAs / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D019636:Neurodegenerative Diseases / Q000188:drug therapy; D009473:Neuronal Plasticity / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000070416:Antagomirs; D035683:MicroRNAs